181514-21-6

Basic information

• Product Name: N-(4-BROMOPHENETHYL)-2,2,2-TRIFLUOROACETAMIDE
• Synonyms: N-(4-BROMOPHENETHYL)-2,2,2-TRIFLUOROACETAMIDE;N-(4-BROMOPHENETHYL)-2,2,2-TRIFLUOROACETAMIDE(WX192143)
• CAS NO: 181514-21-6
• Molecular Formula: C₁₀H₉BrF₃NO
• Molecular Weight: 296.08
• Mol File: 181514-21-6.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-BROMOPHENETHYL)-2,2,2-TRIFLUOROACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-BROMOPHENETHYL)-2,2,2-TRIFLUOROACETAMIDE(181514-21-6)
• EPA Substance Registry System: N-(4-BROMOPHENETHYL)-2,2,2-TRIFLUOROACETAMIDE(181514-21-6)

Safety Data

• Hazardous Substances Data: 181514-21-6(Hazardous Substances Data)

Upstream product

• 206559-45-7 2-(4-Bromo-phenyl)ethylamine hydrobromide 
• 407-25-0 trifluoroacetic anhydride 
• 73918-56-6 4-Bromophenethylamine 

Downstream Products

• 500303-68-4 4-bromo-2-nitrophenethylamine 
• 253801-24-0 7-formyl-3,4-dihydroisoquinolin-2(1H)-carboxylic acid t-butyl ester 
• 1391212-56-8 7-bromo-1-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline 
• 1254103-21-3 N-[2-(4-bromo-3-nitrophenyl)ethyl]-2,2,2-trifluoroacetamide 
• 181514-35-2 1-(7-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one 
• 17680-55-6 7-bromo-1,2,3,4-tetrahydroisoquinoline 
• 252331-63-8 1-(6-bromo-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoro-ethanone 
• 500303-67-3 N-[2-(4-bromo-2-nitrophenyl)ethyl]-2,2,2-trifluoroacetamide 
• 181514-22-7 methyl 4-(2-(2,2,2-trifluoroacetamido)ethyl)benzoate 

Relevant articles and documents

PYRAZOLOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING CANCER, AUTOIMMUNE DISEASE AND BRAIN DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.

Pyrrolo pyrimidine ring compound, its use and pharmaceutical composition (by machine translation)

The invention relates to an as TLR7 agonist of the pyrrolo pyrimidine compounds, specifically on a compound of formula (I) compound or its pharmaceutically acceptable salt, preparation method thereof, containing the compounds of the pharmaceutical composition, and its use for the preparation of antiviral drug use. Formula (I) (by machine translation)

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.